fda compounded semaglutide decision US to reconsider barring versions of Lilly weight loss drug Hims & Hers stock falls

Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta

Obesity is also a leading driver of gastrointestinal (GI) and hepatobiliary cancers, from colorectal cancer to hepatocellular carcinoma, making any therapy that modifies obesity-related cancer risk directly relevant to gastroenterology practice

Olea Lopez AL, Johnson L

It is not known if compounded semaglutide will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people

As part of a GLP-1 weight loss program, semaglutide can: Increase feelings of fullness after meals Reduce appetite and cravings Slow gastric emptying, so food stays in the stomach longer Support more stable blood sugar levels In large clinical trials, patients using semaglutide for obesity along with diet and activity changes lost, on average, around 1015% or more of their body weight over time, with many achieving at least 510% weight losslevels often considered clinically meaningful for health improvements